Technical Analysis for CLVS - Clovis Oncology, Inc.

Grade Last Price % Change Price Change
grade D 6.31 -3.66% -0.24
CLVS closed down 3.66 percent on Thursday, November 14, 2019, on 2.78 times normal volume. Due to the stock's strong uptrend, it may remain overbought for a while. So, if you're looking for a reason to sell, don't put too much weight on it being overbought.

Earnings due: Dec 1

*** please verify all earnings dates ***

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Strong Down Up Up
See historical CLVS trend table...

Date Alert Name Type % Chg
Parabolic Rise Strength 0.00%
Stochastic Reached Overbought Strength 0.00%
Upper Bollinger Band Walk Strength 0.00%
Wide Bands Range Expansion 0.00%
Above Upper BB Strength 0.00%
Overbought Stochastic Strength 0.00%
Upper Bollinger Band Touch Strength 0.00%
Pocket Pivot Bullish Swing Setup -3.66%
Volume Surge Other -3.66%
Parabolic Rise Strength -3.66%

Older signals for CLVS ...

Free Daily (Stock) Chart Reading

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:
Clovis Oncology, Inc., a biopharmaceutical company, focuses on acquiring, developing, and commercializing anti-cancer agents in the United States, Europe, and internationally. The company has two clinical development programs and one drug discovery program underway. Its clinical development programs include CO-1686, which is Phase I/II study is an oral epidermal growth factor receptor (EGFR), mutant-selective covalent inhibitor that is the subject of a development program for the treatment of non-small cell lung cancer in patients with activating EGFR mutations, as well as the primary resistance mutation, T790M; and rucaparib, an oral inhibitor of poly (ADP-ribose) polymerase that is being explored in Phase I/II clinical trials for ovarian and breast cancer patients with BRCA mutations and other DNA repair deficiencies. The company's drug discovery program includes its mutant cKit inhibitor discovery program targeting the resistance mutations that occur in the majority of gastrointestinal stromal tumor patients and result in disease progression. It has license agreements with Avila Therapeutics, Inc. and Pfizer Inc.; a drug discovery collaboration agreement with Array BioPharma Inc.; and collaborations with Roche Molecular Systems and Foundation Medicine, Inc. Clovis Oncology, Inc. was founded in 2009 and is headquartered in Boulder, Colorado.
Biopharmaceutical Disease Chemical Compounds Organic Compounds Drug Discovery Breast Cancer Non Small Cell Lung Cancer Lung Cancer Lactams Treatment Of Non Small Cell Lung Cancer Epidermal Growth Factor Receptor Indoles Gastrointestinal Stromal Tumor Heterocyclic Compounds
Is CLVS a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 2 bullish, 2 bearish and 1 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicator Value
52 Week High 32.05
52 Week Low 2.93
Average Volume 5,687,157
200-Day Moving Average 14.1531
50-Day Moving Average 4.2365
20-Day Moving Average 4.109
10-Day Moving Average 4.844
Average True Range 0.6454
ADX 39.07
+DI 41.145
-DI 7.6262
Chandelier Exit (Long, 3 ATRs ) 5.0638
Chandelier Exit (Short, 3 ATRs ) 4.8662
Upper Bollinger Band 6.3239
Lower Bollinger Band 1.8941
Percent B (%b) 1.0
BandWidth 107.807252
MACD Line 0.523
MACD Signal Line 0.1512
MACD Histogram 0.3718
Fundamentals Value
Market Cap 308.16 Million
Num Shares 48.8 Million
EPS -8.90
Price-to-Earnings (P/E) Ratio -0.71
Price-to-Sales 167.14
Price-to-Book 10.56
PEG Ratio 0.12
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 7.86
Resistance 3 (R3) 7.91 7.46 7.60
Resistance 2 (R2) 7.46 7.06 7.43 7.51
Resistance 1 (R1) 6.88 6.82 6.66 6.83 7.43
Pivot Point 6.43 6.43 6.31 6.40 6.43
Support 1 (S1) 5.85 6.03 5.63 5.80 5.19
Support 2 (S2) 5.40 5.79 5.37 5.11
Support 3 (S3) 4.82 5.40 5.02
Support 4 (S4) 4.77